

90 PERCENT OF RADIATION ONCOLOGY PROFESSIONALS SURVEYED BELIEVE ELECTRONIC BRACHYTHERAPY IS AN EXCITING NEW CANCER TREATMENT TOOL

Axxent™ Electronic Brachytherapy System, Pending FDA Clearance, Highlighted as a Quantum Leap in Therapy Delivery During ASTRO Plenary Session

DENVER, Colo., Nov. 4, 2005 – Tens of thousands of women suffering from breast cancer opt for mastectomies or for lumpectomies without radiation therapy, despite significant clinical evidence demonstrating equivalent survival rates for breast conserving therapy. This may change with the widespread adoption of Electronic Brachytherapy, a new technology designed to deliver localized, non-radioactive radiation treatment directly to cancer sites, according to a survey of radiation oncology professionals at the recent American Society for Therapeutic Radiology and Oncology (ASTRO) Meeting.

The survey, commissioned by Xoft, Inc., measured radiation oncology professionals' knowledge and anticipated acceptance of Electronic Brachytherapy technology, a proprietary platform designed to deliver non-radioactive, isotope-free radiation treatment in a minimally-shielded clinical setting under the supervision of a radiation oncologist. While some 80 percent of the respondents first learned of the novel technology, pending FDA clearance, at ASTRO, interest in Electronic Brachytherapy was very high as evidenced by attendance of more than 270 professionals at a technology symposium hosted by Xoft.

The technology was also highlighted in a plenary session as an important innovation in the delivery of radiation therapy. According to Steve Leibel, MD, Medical Director, Stanford Cancer Center at the Stanford University Medical Center, "The landscape of radiation oncology is changing. Technical innovations have led to significant paradigm changes. There has been a quantum leap in therapy delivery with a variety of different innovations for applying radiation therapy. We can take for example a technical innovation in brachytherapy called Electronic Brachytherapy. Imagine the possibility of having a miniaturized x-ray tube replace radioisotopes and to be able to turn the brachytherapy source on and off whenever you want."

The survey found that some 90 percent of the respondents believe that Electronic Brachytherapy is an exciting new radiation therapy technology for the treatment of cancer. And despite many having just learned of the technology, a solid majority said that once Electronic Brachytherapy received clearance from the FDA they would likely incorporate the technology into their practice. This should allow breast cancer patients to have broader, easier access and more options for receiving their radiation treatment after lumpectomy.

Safety-related benefits of Electronic Brachytherapy were cited by two-thirds of the survey respondents as the most important characteristic that distinguishes this technology from other currently available radiation treatments. Specifically, respondents called out the ability to eliminate radioactive

isotopes, that heavy treatment room shielding was not required, and that the technology would enable them to deliver safe, high dose rate radiation directly into the tumor bed.

Used to treat cancer for more than 100 years, radiation therapy is administered after breast-sparing surgery to kill any stray cancer cells that might remain in the breast and is proven to reduce the rate of local recurrences and improve long-term survival. Ample data from several randomized controlled clinical studies has demonstrated that radiation therapy is an essential component of treatment for breast cancer when the patient wishes to conserve her breast with lumpectomy surgery as opposed to undergoing a full mastectomy. More recent studies also have shown that many patients opt out of receiving radiation therapy due to time, distance, or difficulty accessing radiation therapy centers.

“We are very encouraged to see such a large, positive response to Electronic Brachytherapy with nearly 300 people attending our symposium and Dr. Leibel recognizing its potential in his keynote address at the ASTRO Presidential Course,” said Michael Klein, president and CEO, Xoft, Inc. “The message from the ASTRO meeting is clear – radiation oncology professionals want a new and less-burdensome tool to perform certain radiation therapy procedures and many believe that Electronic Brachytherapy may be the solution.”

The Axxent Electronic Brachytherapy System uses disposable micro-miniature X-ray radiation sources to deliver ionizing radiation treatment directly to tumor beds. In its first indication for use, the Axxent System can be used to deliver a course of radiation therapy for early stage breast cancer. It gives radiation oncologists the flexibility to deliver radiation at multiple energy levels, while at the same time eliminating the need for heavily shielded environments so that it can be used in a broader range of clinical settings. This may accelerate patient choice of breast sparing lumpectomy surgery with adjuvant radiation therapy over the alternative of a full mastectomy.

About Xoft, Inc.

Xoft is developing leading-edge new technologies for the practice of radiation oncology through Electronic Brachytherapy, which utilizes proprietary miniaturized X-ray tube technology. The Axxent Electronic Brachytherapy System, Xoft's first treatment system, is designed for use in Accelerated Partial Breast Irradiation for the treatment of early stage breast cancer. This solution provides a therapeutic dose of intracavitary radiation directly to the region at risk without the complex handling and resource logistics necessary when performing brachytherapy using radioactive isotopes.

#

Axxent is a trademark of Xoft, Inc.

Media Contact:

Chris K. Joseph
510/339-2293
chris@ckjcomm.com